About: Current Issues in Ventilator-Associated Pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Current Issues in Ventilator-Associated Pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Current Issues in Ventilator-Associated Pneumonia
topic	covid:e177a101aa96857e6defeb81645acf14bb813384#this
source	PMC
abstract	Infections in critically ill patients account for a major proportion of the mortality, morbidity, and cost associated with their care. Infection rate in critically ill patients are about 40% and may be 50–60% in those remaining in the intensive care unit (ICU) for more then 5 days.(1,2) Pneumonia acquired in the ICU (after 48 h intuba tion) ranges from 10% to 65%,(3,4) and respiratory infections account for 30–60% of all infections acquired in the ICU(.5,6) Mortality rates of ventilator-associated pneumonia (VAP) have been very high (30–70%) and may account for 15% of all deaths in the ICU. (7–9) When controlled for severity of underlying disease and other factors the attributable mortality of VAP range from 0% to 50% absolute increase, and prolonged length of ICU stay (range 5–13 days).(10) In a recent review of the clinical and economic consequences of VAP from analysis of studies published after 1990, the findings were: 10–20% of ICU-ventilated patients will develop VAP, and are twice as likely to die compared to patients without VAP, with 6 extra days in the ICU and an additional US$10019 hospital cost per case.(11) Empiric broad-spectrum antimicrobials in the ICU for presumed pneumonia has contributed substantially to the worldwide increase in antibiotic-resistant bacteria in hospitals. This has compounded the problem of increasing morbidity, mortality, and cost because of the challenge posed by these difficult-to-treat microorganisms, particularly the use of expensive drugs and need for isolation.
has issue date	2009-01-01(xsd:dateTime)
bibo:doi	10.1007/978-0-387-84841-9_3
has license	no-cc
sha1sum (hex)	e177a101aa96857e6defeb81645acf14bb813384
schema:url	https://doi.org/10.1007/978-0-387-84841-9_3
resource representing a document's title	Current Issues in Ventilator-Associated Pneumonia
has PubMed Central identifier	PMC7121435
schema:publication	Emerging Issues and Controversies in Infectious Disease
resource representing a document's body	covid:e177a101aa96857e6defeb81645acf14bb813384#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/e177a101aa96857e6defeb81645acf14bb813384
is schema:about of	named entity 'drugs' named entity 'proportion' named entity 'Infection' named entity 'factors' named entity 'account' named entity 'CONSEQUENCES' named entity 'DIAGNOSIS' named entity 'VAP' named entity 'Pneumonia' named entity 'days' named entity 'VAP' named entity 'consequences' named entity 'length' named entity 'morbidity' named entity 'antimicrobials' named entity 'Infections' named entity 'intensive care unit (ICU)' named entity 'ICU' named entity 'hospital' named entity 'VAP' named entity 'cost' named entity 'microorganisms' named entity 'antimicrobials' named entity 'intubation' named entity 'VAP' named entity 'antibiotic-resistant bacteria' named entity 'critically ill patients' named entity 'ICU' named entity 'VAP' named entity 'morbidity' named entity 'Ventilator-Associated Pneumonia' named entity 'expensive' named entity 'microorganism' named entity 'antibiotics' named entity 'ICU' named entity 'antibiotic' named entity 'ertapenem' named entity 'mortality rate' named entity 'gram-negative' named entity 'gram-negative bacilli' named entity 'randomized study' named entity 'mechanical ventilation' named entity 'antibiotic prophylaxis' named entity 'aspirates' named entity 'transbronchial' named entity 'dental plaque' named entity 'cephalosporins' named entity 'Pseudomonas aeruginosa' named entity 'Neutrophils' named entity 'prophylaxis' named entity 'pneumonia' named entity 'antimicrobial therapy' named entity 'meta-analyses' named entity 'VAP' named entity 'staphylococci' named entity 'broad-spectrum' named entity 'respiratory tract' named entity 'VAP' named entity 'tube feeding' named entity 'culture results' named entity 'antimicrobial prophylaxis' named entity 'protected specimen brush' named entity 'gram-positive bacterial infections' named entity 'mechanical ventilation' named entity 'VAP' named entity 'Canada' named entity 'pyloric' named entity 'sulbactam' named entity 'respiratory secretions' named entity 'Fiberoptic' named entity 'tracheostomies' named entity 'oropharyngeal' named entity 'VAP' named entity 'chronic obstructive pulmonary disease' named entity 'gram-negative bacilli' named entity 'prophylaxis' named entity 'resistant strains' named entity 'prophylaxis' named entity 'decontamination' named entity 'endobronchial' named entity 'gram-positive bacteria' named entity 'S. aureus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software